Not to be confused with Cytokinin.
Their definite distinction from hormones is still part of ongoing research.
Cytokines are produced by a broad range of cells, including immune cells like macrophages, B lymphocytes, T lymphocytes and mast cells, as well as endothelial cells, fibroblasts, and various stromal cells; a given cytokine may be produced by more than one type of cell.
They act through cell surface receptors and are especially important in the immune system; cytokines modulate the balance between humoral and cell-based immune responses, and they regulate the maturation, growth, and responsiveness of particular cell populations.
Some cytokines enhance or inhibit the action of other cytokines in complex ways.
They are different from hormones, which are also important cell signaling molecules.
Hormones circulate in higher concentrations, and tend to be made by specific kinds of cells.
The word comes from Greek: cyto, from Greek "κύτος" kytos "cavity, cell" + kines, from Greek "κίνησις" kinēsis "movement".
Interferon-alpha, an interferon type I, was identified in 1957 as a protein that interfered with viral replication.
Macrophage migration inhibitory factor (MIF) was identified simultaneously in 1966 by John David and Barry Bloom.
In 1969, Dudley Dumonde proposed the term "lymphokine" to describe proteins secreted from lymphocytes and later, proteins derived from macrophages and monocytes in culture were called "monokines".
In 1974, Stanley Cohen published an article describing the production of MIF in virus-infected allantoic membrane and kidney cells, showing its production is not limited to immune cells.
This led to his proposal of the term cytokine.
Ogawa described the early acting growth factors, intermediate acting growth factors and late acting growth factors.
Difference from hormones
Classic hormones circulate in nanomolar (10 M) concentrations that usually vary by less than one order of magnitude.
In contrast, some cytokines (such as IL-6) circulate in picomolar (10 M) concentrations that can increase up to 1,000 times during trauma or infection.
The widespread distribution of cellular sources for cytokines may be a feature that differentiates them from hormones.
The current terminology refers to cytokines as immunomodulating agents.
A contributing factor to the difficulty of distinguishing cytokines from hormones is that some immunomodulating effects of cytokines are systemic rather than local.
Essentially, cytokines are not limited to their immunomodulatory status as molecules.
Because cytokines are characterised by considerable redundancy and pleiotropism, such distinctions, allowing for exceptions, are obsolete.
- The term interleukin was initially used by researchers for those cytokines whose presumed targets are principally white blood cells (leukocytes). It is now used largely for designation of newer cytokine molecules and bears little relation to their presumed function. The vast majority of these are produced by T-helper cells.
- Lymphokines: produced by lymphocytes
- Monokines: produced exclusively by monocytes
- Interferons: involved in antiviral responses
- Colony stimulating factors: support the growth of cells in semisolid media
- Chemokines: mediate chemoattraction (chemotaxis) between cells.
Structural homogeneity has been able to partially distinguish between cytokines that do not demonstrate a considerable degree of redundancy so that they can be classified into four types:
- The four-α-helix bundle family (InterPro: ): member cytokines have three-dimensional structures with a bundle of four α-helices. This family, in turn, is divided into three sub-families:
- the IL-2 subfamily. This is the largest family. It contains several non-immunological cytokines including erythropoietin (EPO) and thrombopoietin (TPO). They can be grouped into long-chain and short-chain cytokines by topology. Some members share the common gamma chain as part of their receptor.
- the interferon (IFN) subfamily.
- the IL-10 subfamily.
- The IL-17 family, which has yet to be completely characterized, though member cytokines have a specific effect in promoting proliferation of T-cells that cause cytotoxic effects.
A classification that proves more useful in clinical and experimental practice outside of structural biology divides immunological cytokines into those that enhance cellular immune responses, type 1 (TNFα, IFN-γ, etc.), and those that enhance antibody responses, type 2 (TGF-β, IL-4, IL-10, IL-13, etc.).
A key focus of interest has been that cytokines in one of these two sub-sets tend to inhibit the effects of those in the other.
The fact that cytokines themselves trigger the release of other cytokines and also lead to increased oxidative stress makes them important in chronic inflammation, as well as other immunoresponses, such as fever and acute phase proteins of the liver (IL-1,6,12, IFN-a).
Cytokines also play a role in anti-inflammatory pathways and are a possible therapeutic treatment for pathological pain from inflammation or peripheral nerve injury.
There are both pro-inflammatory and anti-inflammatory cytokines that regulate this pathway.
Main article: Cytokine receptor
In recent years, the cytokine receptors have come to demand the attention of more investigators than cytokines themselves, partly because of their remarkable characteristics and partly because a deficiency of cytokine receptors has now been directly linked to certain debilitating immunodeficiency states.
In this regard, and also because the redundancy and pleomorphism of cytokines are, in fact, a consequence of their homologous receptors, many authorities think that a classification of cytokine receptors would be more clinically and experimentally useful.
A classification of cytokine receptors based on their three-dimensional structure has, therefore, been attempted.
Such a classification, though seemingly cumbersome, provides several unique perspectives for attractive pharmacotherapeutic targets.
- Immunoglobulin (Ig) superfamily, which are ubiquitously present throughout several cells and tissues of the vertebrate body, and share structural homology with immunoglobulins (antibodies), cell adhesion molecules, and even some cytokines. Examples: IL-1 receptor types.
- Hemopoietic Growth Factor (type 1) family, whose members have certain conserved motifs in their extracellular amino-acid domain. The IL-2 receptor belongs to this chain, whose γ-chain (common to several other cytokines) deficiency is directly responsible for the x-linked form of Severe Combined Immunodeficiency (X-SCID).
- Interferon (type 2) family, whose members are receptors for IFN β and γ.
- Tumor necrosis factors (TNF) (type 3) family, whose members share a cysteine-rich common extracellular binding domain, and includes several other non-cytokine ligands like CD40, CD27 and CD30, besides the ligands on which the family is named.
- Seven transmembrane helix family, the ubiquitous receptor type of the animal kingdom. All G protein-coupled receptors (for hormones and neurotransmitters) belong to this family. Chemokine receptors, two of which act as binding proteins for HIV (CD4 and CCR5), also belong to this family.
- Interleukin-17 receptor (IL-17R) family, which shows little homology with any other cytokine receptor family. Structural motifs conserved between members of this family include: an extracellular fibronectin III-like domain, a transmembrane domain and a cytoplasmic SERIF domain. The known members of this family are as follows: IL-17RA, IL-17RB, IL-17RC, IL17RD and IL-17RE.
Each cytokine has a matching cell-surface receptor.
Subsequent cascades of intracellular signaling then alter cell functions.
This may include the upregulation and/or downregulation of several genes and their transcription factors, resulting in the production of other cytokines, an increase in the number of surface receptors for other molecules, or the suppression of their own effect by feedback inhibition.
The effect of a particular cytokine on a given cell depends on the cytokine, its extracellular abundance, the presence and abundance of the complementary receptor on the cell surface, and downstream signals activated by receptor binding; these last two factors can vary by cell type.
Cytokines are characterized by considerable redundancy, in that many cytokines appear to share similar functions.
It seems to be a paradox that cytokines binding to antibodies have a stronger immune effect than the cytokine alone.
This may lead to lower therapeutic doses.
It has been shown that inflammatory cytokines cause an IL-10-dependent inhibition of T-cell expansion and function by up-regulating PD-1 levels on monocytes, which leads to IL-10 production by monocytes after binding of PD-1 by PD-L.
Adverse reactions to cytokines are characterized by local inflammation and/or ulceration at the injection sites.
Occasionally such reactions are seen with more widespread papular eruptions.
Roles in health and disease
Cytokines are often involved in several developmental processes during embryonic development.
Cytokines are crucial for fighting off infections and in other immune responses.
Normal tissue integrity is preserved by feedback interactions between diverse cell types mediated by adhesion molecules and secreted cytokines; disruption of normal feedback mechanisms in cancer threatens tissue integrity.
Over-secretion of cytokines can trigger a dangerous cytokine storm syndrome.
Cytokine storms may have been the cause of severe adverse events during a clinical trial of TGN1412.
Cytokine storms are also suspected to be the main cause of death in the 1918 "Spanish Flu" pandemic.
Deaths were weighted more heavily towards people with healthy immune systems, because of their ability to produce stronger immune responses, with dramatic increases in cytokine levels.
Another example of cytokine storm is seen in acute pancreatitis.
Current data suggest cytokine storms may be the source of extensive lung tissue damage and dysfunctional coagulation in COVID-19 infections.
Medical use as drugs
Recombinant cytokines being used as drugs as of 2014 include:
- Bone morphogenetic protein (BMP), used to treat bone-related conditions
- Erythropoietin (EPO), used to treat anemia
- Granulocyte colony-stimulating factor (G-CSF), used to treat neutropenia in cancer patients
- Granulocyte macrophage colony-stimulating factor (GM-CSF), used to treat neutropenia and fungal infections in cancer patients
- Interferon alfa, used to treat hepatitis C and multiple sclerosis
- Interferon beta, used to treat multiple sclerosis
- Interleukin 2 (IL-2), used to treat cancer.
- Interleukin 11 (IL-11), used to treat thrombocytopenia in cancer patients.
- Interferon gamma is used to treat chronic granulomatous disease and osteopetrosis
Credits to the contents of this page go to the authors of the corresponding Wikipedia page: en.wikipedia.org/wiki/Cytokine.